Skip to content

Viracta Therapeutics, Inc.

CIK 0001061027

← back to feed
Revenue (TTM)
$120K
−94.2% YoY Q3 Nov 2024
Net Income (TTM)
−$42.12M
−3.8% YoY Q3 Nov 2024
EPS Diluted (TTM)
−$1.08
−1.5% YoY Q3 Nov 2024
Gross Margin
—
Q3 Nov 2024
Operating Margin
-38,437.5%
Q3 Nov 2024
Net Margin
-35,103.3%
Q3 Nov 2024
Free Cash Flow (TTM)
−$28.14M
Q3 Nov 2024
Cash
$13.13M
Q3 Nov 2024
Total Debt
$16.91M
Q3 Nov 2024
Shares Outstanding
39.74M sh
Q3 Nov 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings